Sector News

India’s Strides to buy Australia, Mauritius drug assets from Aspen for $300 mln

May 21, 2015
Life sciences
(Reuters) – Indian drugmaker Strides Arcolab Ltd has agreed to buy businesses in Australia and Mauritius from South Africa’s Aspen Pharmacare Holdings Ltd , paying $300 million to expand its footprint in markets set for brisk growth.
 
For about A$380 million ($300 million), Strides is buying a generic drug operation in Australia that brought in sales of A$120 million in the year ended in June 2014, the firm said in a stock exchange filing on Thursday. (bit.ly/1LeoPOx)
 
The deal also covers the sale by Aspen’s Mauritius unit of a portfolio of six branded prescription drugs to Strides’ Singapore business. Strides, a major manufacturer of soft gelatin capsules, said it will also gain access to Aspen’s product pipeline that includes some “major product launches in the next six months”.
 
Australia’s pharmaceutical market is expected to grow to $32.1 billion by 2020 from $22.7 billion in 2013, according to market research firm Global Data, driven by rising health insurance cover and an increasing elderly population.
 
Invesors welcomed the news, sending Strides shares 5 percent higher in Mumbai at 0734 GMT, while the broader market was down 0.17 percent.
 
In its own statement, Aspen said the deals were in line with its existing strategy “to focus attention in areas where most value can be added”.
 
The moves are the latest in a series by Strides to streamline its portfio of assets. It bought Chennai, India-based drug ingredients maker Shasun Pharmaceuticals Ltd for $200 million last September, while in 2013 it sold its injectable drugs unit, Agila Specialties, to U.S. firm Mylan NV for about $1.6 billion.
 
Strides owned Ascent Pharmahealth Ltd in Australia until 2012, when it sold the business to U.S. firm Watson Pharmaceuticals Inc, now called Actavis plc. At the time, Strides said the deal was to sharpen its focus on high-margin, sterile injectable products.
 
Strides said the Australian business will operate under the Arrrow Pharmaceuticals brand and will sell both prescription and non-prescription products, Strides said.
 
The deals will be financed using internal reserves and debt, Strides said, and should be immediately accretive to its earnings per share. The company said it expects the deals to close by the end of the second quarter. ($1 = 1.2674 Australian dollars)
 
(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair and Kenneth Maxwell)

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.